The second sponsor, smaller and working in a rare neuromuscular indication, did something different. Before locking their pivotal trial design, they brought the proposed endpoint, population, and statistical plan to FDA in a Type B meeting and asked directly whether a functional outcome measure under development would be considered adequately validated in that population.